Sun Pharmaceutical Industries Limited vs Zydus Lifesciences Limited
An objective side-by-side of SUNPHARMA and ZYDUSLIFE, both in Pharmaceuticals - Indian - Bulk Drugs & Formln: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: SUNPHARMA Jun 2026 · ZYDUSLIFE Mar 2026
At a glance
- Sun Pharmaceutical Industries Limited is the larger company by market value, about 3.9 times the size of Zydus Lifesciences Limited.
- On trailing earnings, Zydus Lifesciences Limited trades at the lower P/E (27.2 against 37.0).
- Zydus Lifesciences Limited earns the higher return on equity (15.7% against 14.5%).
- Over three years Zydus Lifesciences Limited has grown profits faster (32% a year against 13%).
- Over the past year the share prices returned +16.7% (SUNPHARMA) and +12.0% (ZYDUSLIFE).
| Metric | Sun Pharmaceutical SUNPHARMA |
Zydus Lifesciences ZYDUSLIFE |
|---|---|---|
| Size and price | ||
| Market cap | ₹448,412 Cr | ₹115,810 Cr |
| Share price | ₹1,869 | ₹1,161 |
| Valuation | ||
| P/E | 37.05 | 27.18 |
| P/B | 5.37 | 4.27 |
| EV/EBITDA | 25.38 | 18.71 |
| PEG | 2.85 | 0.85 |
| Dividend yield | 0.9% | 0.1% |
| Profitability | ||
| ROE | 14.5% | 15.7% |
| ROCE | 21.0% | 21.0% |
| Operating margin | 29.8% | 35.5% |
| Sales (TTM) | ₹59,911 Cr | ₹19,316 Cr |
| Net profit (TTM) | ₹12,104 Cr | ₹4,261 Cr |
| Growth | ||
| Latest quarter sales YoY | +10.5% | +16.2% |
| Latest quarter profit YoY | +27.0% | +14.5% |
| Sales CAGR 3Y | +10.0% | +16.0% |
| Profit CAGR 3Y | +13.0% | +32.0% |
| Sales CAGR 5Y | +12.0% | +12.0% |
| Profit CAGR 5Y | +17.0% | +19.0% |
| Financial strength | ||
| Debt/Equity | 0.06 | 0.46 |
| Interest cover | 43.64 | 13.34 |
| Ownership | ||
| Promoter holding | 54.5% | 75.0% |
| Promoter change (4 qtrs) | +0.00 pp | +0.00 pp |
| Price performance | ||
| Return 1M | -1.84% | +4.81% |
| Return 3M | +0.32% | +6.96% |
| Return 1Y | +16.66% | +11.97% |
| Return YTD | +8.68% | +26.98% |
| Technical condition | ||
| Technical score | 35 | 78 |
| RS rating (1-99) | 60.00 | 73.00 |
| % vs 200-DMA | +3.42% | +15.93% |
| RSI (14) | 45.40 | 55.92 |
| % from 52-week high | -8.70% | -3.65% |
